Classic case - Medical and health professional investment - Financing risk management - Shenzhen Efung Investment Management Co. Ltd.

Chipscreen Biosciences

2018 - 10 - 29

Epidaza (Chidamide) is the first marketed innovative drug developed by a Chinese pharmaceutical company. As an oral HDAC inhibitor, Epidaza targets recurrent peripheral T cell lymphoma. Meanwhile, it can also treat other hematological cancer, solid tumor and even HIV combined with other drugs. Multiple clinical trials are conducted in the U.S., Japan, China and Taiwan.

Ascentage Pharma

2018 - 10 - 29

Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Its expertise is in developing inhibitors of protein-protein interactions (PPIs) to restore apoptosisor programmed cell death. There are seven drug candidates in Phase I or II clinical trials in the U.S., Australia and China, including a novel Bcl-2/Bcl-xL inhibitor as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).

Frontier Biotech

2018 - 10 - 29

Frontier Biotech is a research-based, clinical stage pharmaceutical company founded in 2002. The management team have extensive business and development experiences in the US and China pharma/biotech industry. Frontier Biotech leverages China's large patient population, and rapid growing economy and pharmaceutical market, develops innovative pharmaceutical products with worldwide IP protection. Frontier Biotech develops Albuvirtide, the first long-acting anti-HIV drug worldwide, which has been approved by CFDA and launched in the third quarter of 2018. The company is dedicated in the discovery, development and commercialization of innovative therapeutic products for unmet medical needs and under-served patients.